Retrieve available abstracts of 69 articles: HTML format
Single Articles
May 2025
ARMESILLA-DIAZ A, Pilar Arenaz M, Ashby C, Blanco D, et al High-throughput screening of small molecules targeting Mycobacterium tuberculosis
in human iPSC macrophages.
Antimicrob Agents Chemother. 2025 May 27:e0161324. doi: 10.1128/aac.01613. PubMedAbstract available
April 2025
SONI H, Tyagi S, Mane K, Shelke AM, et al The KasA inhibitor JSF-3285 improves the sterilizing activity of
bedaquiline-pretomanid-containing regimens in a mouse model of tuberculosis.
Antimicrob Agents Chemother. 2025 Apr 23:e0013025. doi: 10.1128/aac.00130. PubMedAbstract available
LI D, Li L, Zhang Y, Cheng K, et al Efficacy of novel regimens targeting oxidative phosphorylation in Mycobacterium
tuberculosis.
Antimicrob Agents Chemother. 2025 Apr 22:e0001925. doi: 10.1128/aac.00019. PubMedAbstract available
SZEL V, Phelan JE, Georghiou SB, Dolinger DL, et al The ahpC c-54t compensatory mutation is not always a valid surrogate for
isoniazid resistance in Mycobacterium tuberculosis.
Antimicrob Agents Chemother. 2025 Apr 22:e0026525. doi: 10.1128/aac.00265. PubMedAbstract available
ARDIZZONI E, Mulders W, De Diego Fuertes M, Hayrapetyan A, et al Phenotypic and genotypic resistance to bedaquiline in patients with
multi-drug-resistant tuberculosis-experiences from Armenia.
Antimicrob Agents Chemother. 2025 Apr 9:e0183924. doi: 10.1128/aac.01839. PubMedAbstract available
SAWE S, Tsirizani L, Court R, Gausi K, et al The effect of pregnancy on the population pharmacokinetics of levofloxacin in
South Africans with rifampicin-resistant tuberculosis.
Antimicrob Agents Chemother. 2025 Apr 1:e0162624. doi: 10.1128/aac.01626. PubMedAbstract available
March 2025
PEROUTKA-BIGUS N, Brooks EJ, Ramey ME, D'Erasmo H, et al Contribution of front-line, standard-of-care drugs to bactericidal responses,
resistance emergence, and cure in murine models of easy- or hard-to-treat
tuberculosis disease.
Antimicrob Agents Chemother. 2025 Mar 26:e0190124. doi: 10.1128/aac.01901. PubMedAbstract available
VEVE MP, Kenney RM, Aljundi AM, Dierker MS, et al Multicenter, retrospective cohort study of antimycobacterial treatment-related
harms among patients with non-tuberculosis Mycobacterium infections in the United
States.
Antimicrob Agents Chemother. 2025 Mar 4:e0159624. doi: 10.1128/aac.01596. PubMedAbstract available
February 2025
GHEBREKRISTOS Y, Ahmed A, Beylis N, Singh S, et al Xpert MTB/RIF Ultra-resistant and MTBDRplus-susceptible rifampicin results in
people with tuberculosis: utility of FluoroType MTBDR and deep sequencing.
Antimicrob Agents Chemother. 2025 Feb 7:e0167124. doi: 10.1128/aac.01671. PubMedAbstract available
January 2025
WYNN EA, Dide-Agossou C, Al Mubarak R, Rossmassler K, et al Emergence of antibiotic-specific Mycobacterium tuberculosis phenotypes during
prolonged treatment of mice.
Antimicrob Agents Chemother. 2025 Jan 17:e0131024. doi: 10.1128/aac.01310. PubMedAbstract available
VOGENSEN VB, Singh S, Allende CJ, Engelthaler DM, et al Fluoroquinolones and rifampin combination in the backdrop of heteroresistant
tuberculosis.
Antimicrob Agents Chemother. 2025 Jan 16:e0108424. doi: 10.1128/aac.01084. PubMedAbstract available
December 2024
NDZAMBA B, Denti P, McIlleron H, Smith P, et al Pharmacokinetics of ethambutol and weight banded dosing in South African adults
newly diagnosed with tuberculosis and HIV.
Antimicrob Agents Chemother. 2024 Dec 23:e0120024. doi: 10.1128/aac.01200. PubMedAbstract available
MANSJO M, Espinosa-Gongora C, Samanci I, Groenheit R, et al Performance of a broth microdilution assay for routine minimum inhibitory
concentration determination of 14 anti-tuberculous drugs against the
Mycobacterium tuberculosis complex based on the EUCAST reference protocol.
Antimicrob Agents Chemother. 2024 Dec 18:e0094624. doi: 10.1128/aac.00946. PubMedAbstract available
KOMM OD, Tyagi S, Garcia A, Almeida D, et al Contribution of telacebec to novel drug regimens in a murine tuberculosis model.
Antimicrob Agents Chemother. 2024 Dec 9:e0096224. doi: 10.1128/aac.00962. PubMedAbstract available
November 2024
VOCAT A, Luraschi-Eggemann A, Antoni C, Cathomen G, et al Real-time evaluation of macozinone activity against Mycobacterium tuberculosis
through bacterial nanomotion analysis.
Antimicrob Agents Chemother. 2024 Nov 27:e0131824. doi: 10.1128/aac.01318. PubMedAbstract available
October 2024
SNOBRE J, Meehan CJ, Mulders W, Rigouts L, et al Frameshift mutations in the mmpR5 gene can have a bedaquiline-susceptible
phenotype by retaining a protein structure and function similar to wild-type
Mycobacterium tuberculosis.
Antimicrob Agents Chemother. 2024 Oct 24:e0085424. doi: 10.1128/aac.00854. PubMedAbstract available
MAITRE T, Godmer A, Mory C, Chauffour A, et al Levofloxacin activity at increasing doses in a murine model of
fluoroquinolone-susceptible and -resistant tuberculosis.
Antimicrob Agents Chemother. 2024 Oct 16:e0058324. doi: 10.1128/aac.00583. PubMedAbstract available
GOH JJN, Wang Q, Zhang N, de Castro Suarez N, et al Prospectively predicting BPaMZ phase IIb/III trial outcomes using a translational
mouse-to-human platform.
Antimicrob Agents Chemother. 2024;68:e0061524. PubMedAbstract available
September 2024
ENCINAS L, Li S-Y, Rullas-Trincado J, Tasneen R, et al Contribution of direct InhA inhibitors to novel drug regimens in a mouse model of
tuberculosis.
Antimicrob Agents Chemother. 2024 Sep 30:e0035724. doi: 10.1128/aac.00357. PubMedAbstract available
BAUMAN AA, Sarathy JP, Kaya F, Massoudi LM, et al Spectinamide MBX-4888A exhibits favorable lesion and tissue distribution and
promotes treatment shortening in advanced murine models of tuberculosis.
Antimicrob Agents Chemother. 2024 Sep 30:e0071624. doi: 10.1128/aac.00716. PubMedAbstract available
ALLEN R, Ames L, Baldin VP, Butts A, et al An arylsulfonamide that targets cell wall biosynthesis in Mycobacterium
tuberculosis.
Antimicrob Agents Chemother. 2024 Sep 26:e0103724. doi: 10.1128/aac.01037. PubMedAbstract available
POONAWALA H, Zhang Y, Kuchibhotla S, Green AG, et al Erratum for Poonawala et al., "Transcriptomic responses to antibiotic exposure in
Mycobacterium tuberculosis".
Antimicrob Agents Chemother. 2024 Sep 19:e0135424. doi: 10.1128/aac.01354. PubMed
August 2024
MARTINI MC, Alonso MN, Cafiero JH, Xiao J, et al Loss of glycerol catabolism confers carbon-source-dependent artemisinin
resistance in Mycobacterium tuberculosis.
Antimicrob Agents Chemother. 2024 Aug 28:e0064524. doi: 10.1128/aac.00645. PubMedAbstract available
July 2024
ROBERTS AH, Moon CW, Faulkner V, Kendall SL, et al EfpA is required for regrowth of Mycobacterium tuberculosis following isoniazid
exposure.
Antimicrob Agents Chemother. 2024 Jul 22:e0026124. doi: 10.1128/aac.00261. PubMedAbstract available
SEMERE GEBREYESUS M, Wasmann RE, McIlleron H, Oladokun R, et al Population pharmacokinetics of rifabutin among HIV/TB co-infected children on
lopinavir/ritonavir-based antiretroviral therapy.
Antimicrob Agents Chemother. 2024 Jul 22:e0035424. doi: 10.1128/aac.00354. PubMedAbstract available
WASSERMAN S, Antilus-Sainte R, Abdelgawad N, Odjourian NM, et al Rifabutin central nervous system concentrations in a rabbit model of tuberculous
meningitis.
Antimicrob Agents Chemother. 2024 Jul 19:e0078324. doi: 10.1128/aac.00783. PubMedAbstract available
SIMEON S, Garcia-Cremades M, Savic R, Solans BP, et al Pharmacokinetic-pharmacodynamic modeling of tuberculosis time to positivity and
colony-forming unit to assess the response to dose-ranging linezolid.
Antimicrob Agents Chemother. 2024 Jul 17:e0019024. doi: 10.1128/aac.00190. PubMedAbstract available
June 2024
KURTZHALS ML, Norman A, Svensson E, Lillebaek T, et al Applying whole genome sequencing to predict phenotypic drug resistance in
Mycobacterium tuberculosis: leveraging 20 years of nationwide data from Denmark.
Antimicrob Agents Chemother. 2024 Jun 21:e0043024. doi: 10.1128/aac.00430. PubMedAbstract available
MOTTA I, Cusinato M, Ludman AJ, Lachenal N, et al How much should we still worry about QTc prolongation in rifampicin-resistant
tuberculosis? ECG findings from TB-PRACTECAL clinical trial.
Antimicrob Agents Chemother. 2024 Jun 6:e0053624. doi: 10.1128/aac.00536. PubMedAbstract available
NEGATU DA, Aragaw WW, Dartois V, Dick T, et al A pairwise approach to revitalize beta-lactams for the treatment of TB.
Antimicrob Agents Chemother. 2024;68:e0003424. PubMedAbstract available
WALSH KF, Lee MH, Zainabadi K, Vilbrun SC, et al High variance in quantification of Mycobacterium tuberculosis at low bacterial
loads and with differentially detectable mycobacteria.
Antimicrob Agents Chemother. 2024 Jun 3:e0160123. doi: 10.1128/aac.01601. PubMedAbstract available
May 2024
YU W, Ju Y, Han X, Tian X, et al Bactericidal and sterilizing activity of sudapyridine-clofazimine-TB47 combined
with linezolid or pyrazinamide in a murine model of tuberculosis.
Antimicrob Agents Chemother. 2024 May 1:e0012424. doi: 10.1128/aac.00124. PubMedAbstract available
April 2024
KENGO A, Nabeemeeah F, Denti P, Sabet R, et al Assessing potential drug-drug interactions between clofazimine and other
frequently used agents to treat drug-resistant tuberculosis.
Antimicrob Agents Chemother. 2024 Apr 10:e0158323. doi: 10.1128/aac.01583. PubMedAbstract available
POONAWALA H, Zhang Y, Kuchibhotla S, Green AG, et al Transcriptomic responses to antibiotic exposure in Mycobacterium tuberculosis.
Antimicrob Agents Chemother. 2024 Apr 8:e0118523. doi: 10.1128/aac.01185. PubMedAbstract available
March 2024
LYONS MA, Obregon-Henao A, Ramey ME, Bauman AA, et al Use of multiple pharmacodynamic measures to deconstruct the Nix-TB regimen in a
short-course murine model of tuberculosis.
Antimicrob Agents Chemother. 2024 Mar 19:e0101023. doi: 10.1128/aac.01010. PubMedAbstract available
VILLELLAS C, Stevenaert F, Remmerie B, Andries K, et al Sub-MIC levels of bedaquiline and clofazimine can select Mycobacterium
tuberculosis mutants with increased MIC.
Antimicrob Agents Chemother. 2024 Mar 12:e0127523. doi: 10.1128/aac.01275. PubMedAbstract available
February 2024
OLIVENCA F, Pires D, Silveiro C, Gama B, et al Ethambutol and meropenem/clavulanate synergy promotes enhanced extracellular and
intracellular killing of Mycobacterium tuberculosis.
Antimicrob Agents Chemother. 2024 Feb 27:e0158623. doi: 10.1128/aac.01586. PubMedAbstract available
LI S-Y, Tyagi S, Soni H, Betoudji F, et al Bactericidal and sterilizing activity of novel regimens combining bedaquiline or
TBAJ-587 with GSK2556286 and TBA-7371 in a mouse model of tuberculosis.
Antimicrob Agents Chemother. 2024 Feb 20:e0156223. doi: 10.1128/aac.01562. PubMedAbstract available
January 2024
SINGH P, Kumar A, Sharma P, Chugh S, et al Identification and optimization of pyridine carboxamide-based scaffold as a drug
lead for Mycobacterium tuberculosis.
Antimicrob Agents Chemother. 2024 Jan 9:e0076623. doi: 10.1128/aac.00766. PubMedAbstract available
December 2023
RUELAS CASTILLO J, Neupane P, Karanika S, Krug S, et al The heme oxygenase-1 metalloporphyrin inhibitor stannsoporfin enhances the
bactericidal activity of a novel regimen for multidrug-resistant tuberculosis in
a murine model.
Antimicrob Agents Chemother. 2023 Dec 22:e0104323. doi: 10.1128/aac.01043. PubMedAbstract available
SINGH S, Gumbo T, Boorgula GD, Thomas TA, et al Omadacycline pharmacokinetics/pharmacodynamics and efficacy against
multidrug-resistant Mycobacterium tuberculosis in the hollow fiber system model.
Antimicrob Agents Chemother. 2023 Dec 22:e0108023. doi: 10.1128/aac.01080. PubMedAbstract available
ALI AM, P Solans B, Hesseling AC, Winckler J, et al Pharmacokinetics and cardiac safety of clofazimine in children with
rifampicin-resistant tuberculosis.
Antimicrob Agents Chemother. 2023 Dec 19:e0079423. doi: 10.1128/aac.00794. PubMedAbstract available
PANDEY S, Vilcheze C, Werngren J, Bainomugisa A, et al Loss-of-function mutations in ndh do not confer delamanid, ethionamide,
isoniazid, or pretomanid resistance in Mycobacterium tuberculosis.
Antimicrob Agents Chemother. 2023 Dec 1:e0109623. doi: 10.1128/aac.01096. PubMedAbstract available
November 2023
VAN DER LAAN LE, Garcia-Prats AJ, McIlleron H, Abdelwahab MT, et al Optimizing dosing of the cycloserine pro-drug terizidone in children with
rifampicin-resistant tuberculosis.
Antimicrob Agents Chemother. 2023 Nov 16:e0061123. doi: 10.1128/aac.00611. PubMedAbstract available
ALMEIDA D, Li S-Y, Lee J, Hafkin B, et al Contezolid can replace linezolid in a novel combination with bedaquiline and
pretomanid in a murine model of tuberculosis.
Antimicrob Agents Chemother. 2023 Nov 15:e0078923. doi: 10.1128/aac.00789. PubMedAbstract available
LANNI F, Antilus Sainte R, Hansen M Jr, Parigi P, et al A preclinical model of TB meningitis to determine drug penetration and activity
at the sites of disease.
Antimicrob Agents Chemother. 2023 Nov 15:e0067123. doi: 10.1128/aac.00671. PubMedAbstract available
October 2023
VAN SCHALKWYK M, Bekker A, Decloedt E, Wang J, et al Pharmacokinetics and safety of first-line tuberculosis drugs rifampin, isoniazid,
ethambutol, and pyrazinamide during pregnancy and postpartum: results from
IMPAACT P1026s.
Antimicrob Agents Chemother. 2023 Oct 26:e0073723. doi: 10.1128/aac.00737. PubMedAbstract available
XIE YL, Modi N, Handler D, Yu S, et al Simplified urine-based method to detect rifampin underexposure in adults with
tuberculosis: a prospective diagnostic accuracy study.
Antimicrob Agents Chemother. 2023 Oct 25:e0093223. doi: 10.1128/aac.00932. PubMedAbstract available
KENGO A, Nabisere R, Gausi K, Musaazi J, et al Dolutegravir pharmacokinetics in Ugandan patients with TB and HIV receiving
standard- versus high-dose rifampicin.
Antimicrob Agents Chemother. 2023 Oct 18:e0043023. doi: 10.1128/aac.00430. PubMedAbstract available
KENGO A, Gausi K, Nabisere R, Musaazi J, et al Unexpectedly low drug exposures among Ugandan patients with TB and HIV receiving
high-dose rifampicin.
Antimicrob Agents Chemother. 2023 Oct 18:e0043123. doi: 10.1128/aac.00431. PubMedAbstract available
RAMEY ME, Kaya F, Bauman AA, Massoudi LM, et al Drug distribution and efficacy of the DprE1 inhibitor BTZ-043 in the C3HeB/FeJ
mouse tuberculosis model.
Antimicrob Agents Chemother. 2023 Oct 4:e0059723. doi: 10.1128/aac.00597. PubMedAbstract available
September 2023
STEMKENS R, Jager V, Dawson R, Diacon AH, et al Drug interaction potential of high-dose rifampicin in patients with pulmonary
tuberculosis.
Antimicrob Agents Chemother. 2023 Sep 28:e0068323. doi: 10.1128/aac.00683. PubMedAbstract available
MEIKLE V, Zhang L, Niederweis M Intricate link between siderophore secretion and drug efflux in Mycobacterium
tuberculosis.
Antimicrob Agents Chemother. 2023 Sep 7:e0162922. doi: 10.1128/aac.01629. PubMedAbstract available
August 2023
WALTER ND, Ernest JP, Dide-Agossou C, Bauman AA, et al Lung microenvironments harbor Mycobacterium tuberculosis phenotypes with distinct
treatment responses.
Antimicrob Agents Chemother. 2023 Aug 11:e0028423. doi: 10.1128/aac.00284. PubMedAbstract available
June 2023
ALI AM, Radtke KK, Hesseling AC, Winckler J, et al QT Interval Prolongation with One or More QT-Prolonging Agents Used as Part of a
Multidrug Regimen for Rifampicin-Resistant Tuberculosis Treatment: Findings from
Two Pediatric Studies.
Antimicrob Agents Chemother. 2023 Jun 26:e0144822. doi: 10.1128/aac.01448. PubMedAbstract available
GRIES R, Dal Molin M, Chhen J, van Gumpel E, et al Characterization of Two Novel Inhibitors of the Mycobacterium tuberculosis
Cytochrome bc(1) Complex.
Antimicrob Agents Chemother. 2023 Jun 26:e0025123. doi: 10.1128/aac.00251. PubMedAbstract available
VAN DER LAAN LE, Garcia-Prats AJ, Schaaf HS, Chirehwa M, et al Erratum for van der Laan et al., "Pharmacokinetics and Dose Optimization
Strategies of Para-Aminosalicylic Acid in Children with Rifampicin-Resistant
Tuberculosis".
Antimicrob Agents Chemother. 2023 Jun 20:e0072023. doi: 10.1128/aac.00720. PubMed
CHANG YS, Li SY, Pertinez H, Betoudji F, et al Using Dynamic Oral Dosing of Rifapentine and Rifabutin to Simulate Exposure
Profiles of Long-Acting Formulations in a Mouse Model of Tuberculosis Preventive
Therapy.
Antimicrob Agents Chemother. 2023 Jun 14:e0048123. doi: 10.1128/aac.00481. PubMedAbstract available
May 2023
XU J, Li D, Shi J, Wang B, et al Bedquiline Resistance Mutations: Correlations with Drug Exposures and Impact on
the Proteome in M. tuberculosis.
Antimicrob Agents Chemother. 2023 May 31:e0153222. doi: 10.1128/aac.01532. PubMedAbstract available
DAWSON R, Diacon AH, Narunsky K, De Jager VR, et al Phase I Single Ascending Dose and Food Effect Study in Healthy Adults and Phase
I/IIa Multiple Ascending Dose Study in Patients with Pulmonary Tuberculosis to
Assess Pharmacokinetics, Bactericidal Activity, Tolerability, and Safety of
OPC-167832.
Antimicrob Agents Chemother. 2023 May 23:e0147722. doi: 10.1128/aac.01477. PubMedAbstract available
MATHIYAZAKAN V, Wong CF, Harikishore A, Pethe K, et al Cryo-Electron Microscopy Structure of the Mycobacterium tuberculosis Cytochrome
bcc:aa(3) Supercomplex and a Novel Inhibitor Targeting Subunit Cytochrome cI.
Antimicrob Agents Chemother. 2023 May 9:e0153122. doi: 10.1128/aac.01531. PubMedAbstract available
April 2023
ZHU Y, Zhu L, Davies Forsman L, Paues J, et al Population Pharmacokinetics and Dose Evaluation of Cycloserine among Patients
with Multidrug-Resistant Tuberculosis under Standardized Treatment Regimens.
Antimicrob Agents Chemother. 2023 Apr 25:e0170022. doi: 10.1128/aac.01700. PubMedAbstract available
NEGATU DA, Aragaw WW, Cangialosi J, Dartois V, et al Side-by-Side Profiling of Oxazolidinones to Estimate the Therapeutic Window
against Mycobacterial Infections.
Antimicrob Agents Chemother. 2023;67:e0165522. PubMedAbstract available
LIU Y, Moodley M, Pasipanodya JG, Gumbo T, et al Determining the Delamanid Pharmacokinetics/Pharmacodynamics Susceptibility
Breakpoint Using Monte Carlo Experiments.
Antimicrob Agents Chemother. 2023;67:e0140122. PubMedAbstract available
March 2023
ECKHARDT E, Li Y, Mamerow S, Schinkothe J, et al Pharmacokinetics and Efficacy of the Benzothiazinone BTZ-043 against Tuberculous
Mycobacteria inside Granulomas in the Guinea Pig Model.
Antimicrob Agents Chemother. 2023 Mar 28:e0143822. doi: 10.1128/aac.01438. PubMedAbstract available
LI SY, Converse PJ, Betoudji F, Lee J, et al Next-Generation Diarylquinolines Improve Sterilizing Activity of Regimens with
Pretomanid and the Novel Oxazolidinone TBI-223 in a Mouse Tuberculosis Model.
Antimicrob Agents Chemother. 2023 Mar 15:e0003523. doi: 10.1128/aac.00035. PubMedAbstract available
ISMAIL N, Dippenaar A, Warren RM, Peters RPH, et al Emergence of Canonical and Noncanonical Genomic Variants following In Vitro
Exposure of Clinical Mycobacterium tuberculosis Strains to Bedaquiline or
Clofazimine.
Antimicrob Agents Chemother. 2023 Mar 9:e0136822. doi: 10.1128/aac.01368. PubMedAbstract available
February 2023
ABDELGAWAD N, Tshavhungwe MP, Rohlwink U, McIlleron H, et al Population Pharmacokinetic Analysis of Rifampicin in Plasma, Cerebrospinal Fluid,
and Brain Extracellular Fluid in South African Children with Tuberculous
Meningitis.
Antimicrob Agents Chemother. 2023 Feb 23:e0147422. doi: 10.1128/aac.01474. PubMedAbstract available
CHIREHWA MT, Resendiz-Galvan JE, Court R, De Kock M, et al Optimizing Moxifloxacin Dose in MDR-TB Participants with or without Efavirenz
Coadministration Using Population Pharmacokinetic Modeling.
Antimicrob Agents Chemother. 2023 Feb 6:e0142622. doi: 10.1128/aac.01426. PubMedAbstract available